Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis

Portal vein thrombosis (PVT) is a common complication of endstage hepatocellular carcinoma (HCC). The aim of our study was to evaluate the role of Homocysteine (Hcy) in HCC patient with PVT. Hcy is a sulphur amino-acid involved in two pathways, trans-sulphuration and remethylation, that involve vitamins B6, B12 and folates. We recruited 54 patients with HCC and PVT, 60 patients with HCC and without PVT and 60 control subjects. We measured serum levels of Hcy, folate, vitamins B6 and B12. The comparison between HCC patients with PVT versus HCC without PVT was shown that mean values of Hcy were 6.4 nmol/L (p<0.0073) higher, LDL cholesterol were 4.8 mg/dl (p<0.0079) lower, vitamin B6 were 4.6 nmol/L(p=0.0544) lower, vitamins B 12 were 22.1 pg/ml (p=0.0001) lower. High serum levels of Hcy are an established thrombotic risk factor in the general population. We found significantly higher levels of Hcy in HCC patients with PVT versus both HCC patients without PVT and controls.

[1]  F. Drago,et al.  D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis , 2018, Clinical and experimental gastroenterology.

[2]  G. Malaguarnera,et al.  Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions , 2018, World journal of hepatology.

[3]  G. Malaguarnera,et al.  Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer , 2018, Biomedicines.

[4]  J. Gracies,et al.  Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[5]  G. Malaguarnera,et al.  Ultrasound as point of care in management of polytrauma and its complication , 2017, Journal of Ultrasound.

[6]  F. Drago,et al.  Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis , 2017, Aging Clinical and Experimental Research.

[7]  K. Chok,et al.  Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. , 2016, World journal of gastroenterology.

[8]  Venerando Rapisarda,et al.  Hepatocellular carcinoma and the risk of occupational exposure. , 2016, World journal of hepatology.

[9]  G. Malaguarnera,et al.  Hepatocellular carcinoma markers in the omics era: the glycomic analysis. , 2014, Hepatobiliary surgery and nutrition.

[10]  S. Salomone,et al.  Homocysteine Serum Levels in Diabetic Patients with Non Proliferative, Proliferative and without Retinopathy , 2014, BioMed research international.

[11]  F. Basile,et al.  Risk of Hepatocellular Carcinoma in Workers Exposed to Chemicals , 2012, Hepatitis monthly.

[12]  J. Bruix,et al.  Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques , 2011, Hepatology.

[13]  F. Basile,et al.  Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma , 2011, Indian Journal of Medical and Paediatric Oncology.

[14]  Jeong Min Lee,et al.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma , 2010, Hepatology international.

[15]  J. Loscalzo,et al.  Quo Vadis: Whither Homocysteine Research? , 2009, Cardiovascular Toxicology.

[16]  B. Daniele,et al.  Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  A. Feinberg.  Phenotypic plasticity and the epigenetics of human disease , 2007, Nature.

[18]  M. Makris,et al.  Hyperhomocysteinemia and venous thrombosis. , 2007, Seminars in hematology.

[19]  A. Bird,et al.  Genomic DNA methylation: the mark and its mediators. , 2006, Trends in biochemical sciences.

[20]  A. Andriulli,et al.  Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors , 2005, European journal of gastroenterology & hepatology.

[21]  P. McBride,et al.  The association of homocysteine and coronary artery disease , 2003, Clinical cardiology.

[22]  A. Bosy-Westphal,et al.  Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. , 2003, The American journal of clinical nutrition.

[23]  R. Franchis,et al.  Low Vitamin B6 Plasma Levels, a Risk Factor for Thrombosis, in Inflammatory Bowel Disease: Role of Inflammation and Correlation With Acute Phase Reactants , 2003, American Journal of Gastroenterology.

[24]  Yuan-Yuan Shi,et al.  Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. , 2001, The Journal of clinical investigation.

[25]  A. Bosy-Westphal,et al.  Increased plasma homocysteine in liver cirrhosis. , 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  T. Orfeo,et al.  Homocysteine Inhibits Inactivation of Factor Va by Activated Protein C* , 2001, The Journal of Biological Chemistry.

[27]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[28]  M. Mccarty,et al.  Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute-phase induction of pyridoxal phosphatase activity. , 2000, Medical hypotheses.

[29]  S. Lynch,et al.  Plasma thiols inhibit hemin-dependent oxidation of human low-density lipoprotein. , 2000, Biochimica et biophysica acta.

[30]  H. Blom,et al.  Hyperhomocysteinemia and Venous Thrombosis: A Meta-analysis , 1998, Thrombosis and Haemostasis.

[31]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[32]  J. Loscalzo,et al.  Homocysteine and atherothrombosis. , 1998, The New England journal of medicine.

[33]  J. Finkelstein,et al.  The metabolism of homocysteine: pathways and regulation , 1998, European Journal of Pediatrics.

[34]  H. Blom,et al.  Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[35]  E. Haber,et al.  Inhibition of Growth and p21 ras Methylation in Vascular Endothelial Cells by Homocysteine but Not Cysteine* , 1997, The Journal of Biological Chemistry.

[36]  J. Ordóñez‐Llanos,et al.  Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia , 1996, Journal of Molecular Medicine.

[37]  T. Starzl,et al.  A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. , 1996, The Journal of surgical research.

[38]  R. D'Agostino,et al.  Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. , 1995, The New England journal of medicine.

[39]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[40]  M. Malinow,et al.  Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. , 1990, Stroke.

[41]  J. Jeppsson,et al.  Folic acid--an innocuous means to reduce plasma homocysteine. , 1988, Scandinavian journal of clinical and laboratory investigation.

[42]  V. Catania,et al.  Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study , 2018 .

[43]  R. Wolfe,et al.  Homocysteine metabolism. , 1999, Annual review of nutrition.